CompletedPhase 3NCT00432614

Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder

Studying Body integrity dysphoria

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sanofi
Principal Investigator: ICD CSD
Sanofi
Intervention: SR58611A(drug)
Enrollment: 510 target
Eligibility: 18-65 years · All sexes
Timeline: 2007 – 2008

Study locations (13)

Sanofi-Aventis Administrative Office, Diegem, Belgium
Sanofi-Aventis Administrative Office, Tatari, Estonia
Sanofi-Aventis Administrative Office, Helsinki, Finland
Sanofi-Aventis Administrative Office, Paris, France
Sanofi-Aventis Administrative Office, Berlin, Germany
Sanofi-Aventis Administrative Office, Athens, Greece
Sanofi-Aventis Administrative Office, Mumbai, India
Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia
Sanofi-Aventis Administrative Office, Casablanca, Morocco
Sanofi-Aventis Administrative Office, Seoul, South Korea
Sanofi-Aventis Administrative Office, Taipei, Taiwan
Sanofi-Aventis Administrative Office, Mégrine, Tunisia
Sanofi-Aventis Administrative Office, Istanbul, Turkey (Türkiye)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00432614 on ClinicalTrials.gov

Other trials for Body integrity dysphoria

Additional recruiting or active studies for the same condition.

See all trials for Body integrity dysphoria →

← Back to all trials